WOMEN'S TRIPLE-NEGATIVE FIRST-LINE STUDY: A PHASE II TRIAL OF PANITUMUMAB, CARBOPLATIN AND PACLITAXEL (PACT) IN PATIENTS WITH LOCALIZED TRIPLE-NEGATIVE BREAST CANCER (TNBC) WITH TUMORS PREDICTED INSENSITIVE TO STANDARD NEOADJUVANT CHEMOTHERAPY: